PanCancer IO 360™ Gene Expression Panel

Facilitating rapid discovery and development of potentially predictive signatures with the most advanced view of immuno-oncology biology. 

The PanCancer IO 360 Gene Expression Panel is a unique 770 gene expression panel for research use only (RUO) that combines vital components involved in the complex interplay between the tumor, microenvironment and immune response in cancer allowing for a multifaceted characterization of disease biology and interrogation of mechanisms of immune evasion.

Developed specifically for translational research, this powerful new panel incorporates 47 potentially predictive Research Use Only (RUO) biological signatures including the 18-gene Tumor Inflammation Signature as recently described in JCI.

  • Tumor, micro-environment, and immune response biology signatures tableTranslational RUO panel for the research of possible predictive signatures for potential immunotherapy companion diagnostics
  • Allows for possible identification of responder/non-responder populations for immunotherapy research
  • Characterize disease biology
  • Interrogate mechanisms of immune evasion

Download Gene Lists:

Learn about our nCounter Analysis System and nSolver™ Analysis Software.


The 2018 Journal of Immunotherapy of Cancer (JITC) “Best Basic Science Paper” awarded to NanoString Scientists

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)


Tumor-Microenvironment-Immune Response

Tumor Immunogenicity Tumor Sensitivity to Immune Attack Inhibitory Immune Mechanisms Stromal Factors Inhibitory Metabolism Anti-Tumor Immune Activity Inhibitory Immune Signaling Immune Cell Population Abundance
Antigen Processing Machinery Apoptosis IDO1 Gene Expression Endothelial Cells Glycolysis Tumor Inflammation Signature (TIS) CTLA4 Gene Expression B Cells NK CD56dim Cells
Antigen Presenting Machinery Expression Loss Tumor Proliferation PD-L1 Gene Expression Stromal Tissue Abundance Hypoxia Cytotoxicity IL10 Gene Expression CD45+ Cells Natural Killer Cell Abundance
Immunoproteasome JAK-STAT Pathway Gene Expression Loss B7-H3 Gene Expression     Interferon Gamma Signaling Inflammatory Chemokines CD8 T Cell T Cells Abundance
MAGE Genes Expression   TGF-Beta Gene Expression     Interferon Signaling Response Myeloid-Derived Inflammatory Signaling Cytotoxic Cells TH1 Cell (TBX21/T-bet) Expression
Loss of Mismatch Repair Gene Expression         Lymphoid Compartment Activity PD-1 Gene Expression Dendritic Cells Treg (FOXP3 Expression)
          MHC Class II Antigen Presentation PD-L2 Gene Expression Exhausted CD8 Cell  
          Myeloid Compartment Activity TIGIT Gene Expression Macrophage  
            ARG1 Gene Expression Mast Cells  
            NOS2 Gene Expression Neutrophils  


Possible predictive signatures measuring IO biology trained through combination of domain knowledge, academic collaborations and mining of public and proprietary data.

PanCancer IO 360 Biological Signatures Supplement

13 Biological Pathways and Processes


Tumor Microenvironment Immune Response
Category/Gene Number Category/Gene Number Category/Gene Number
Release of Cancer Cell Antigens 74 Angiogenesis 40 Cancer Antigen Presentation 95
Cell Cycling and Proliferation 54 Extracellular Matrix Remodelling 43 T cell priming and Activation 151
Tumor Intrinsic Factors 156 Collagens 6 Immune Cells Localization to Tumors 293
Common Signaling Pathways 172 Metastasis 20 Recognition of Cancer Cells by T cells 103
    Killing of Cancers Cells 177
    Myeloid Cell Activity 262
    NK Cell Activity 28
    Immunometabolism 99


20 internal reference genes include overlapping genes from Hallmarks of Cancer PanCancer Collection for cross-panel comparisons.

Tumor Inflammation Signature1

The Tumor Inflammation Signature includes 18 functional genes known to be associated with response to PD-1/PD-L1 inhibitors pathway blockade.

Includes 4 Areas of Immune Biology: IFN-ү-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance genes.

tumor inflammation gene expression signature

The tumor inflammation gene expression signature highlights the complex biology of the host immune microenvironment.

18-gene Tumor Inflammation Signature



View publication and video.

1. Ayers, Mark, et al. "IFN-y-related mRNA profile predicts clinical response to PD-1 blockade." The Journal of Clinical Investigation 127.8 (2017).

Feature Specifications
Number of Targets 770 (Human and Mouse), Including internal reference genes
Sample Input – Standard (No amplification required) 50 – 300 ng
Sample Input – Low Input As little as 10 ng with nCounter RNA Low Input Kit and Panel specific primer pools (sold separately)
IO 360 Panel Standard Synthetic oligonucleotide pool corresponding to all panel gene targets used for normalization
Sample Type(s) FFPE-derived RNA, total RNA, and cell lysates
Customizable Add up to 30 unique genes with Panel-Plus
Time to Results Approximately 24 hours
Data Analysis nSolver Analysis software, IO 360 Data Analysis Service


Development of Gene Expression Signatures Characterizing the Tumor-Immune Interaction

Alessandra Cesano and Sarah Warren. "Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic." Biomedicines (2018).

Ayers, Mark, et al. "IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade.The Journal of Clinical Investigation 127.8 (2017).

Danaher, Patrick, et al. "Gene expression markers of Tumor Infiltrating Leukocytes.Journal for immunotherapy of cancer 5.1 (2017): 18.

Satoh, Jun-ichi, and Hiroko Tabunoki. "A comprehensive profile of ChIP-Seq-based STAT1 target genes suggests the complexity of STAT1-mediated gene regulatory mechanisms.Gene regulation and systems biology 7 (2013): 41.

Becht, Etienne, et al. "Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.Genome biology 17.1 (2016): 218.

Spranger, Stefani, Riyue Bao, and Thomas F. Gajewski. "Melanoma-intrinsic [beta]-catenin signalling prevents anti-tumour immunity.Nature 523.7559 (2015): 231.

Harris, B. H. L., et al. "Gene expression signatures as biomarkers of tumour hypoxia.Clinical Oncology 27.10 (2015): 547-560.

Manson, G., et al. "Biomarkers associated with checkpoint inhibitors.Annals of Oncology 27.7 (2016): 1199-1206.

Blank, Christian U., et al. "The “cancer immunogram”.Science 352.6286 (2016): 658-660.

For Research Use Only. Not for use in diagnostic procedures.